Luteinizing hormone-releasing hormone antagonists

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 12, 2009, Pages 1771-1785

  Mezo, Gbor ^a   Manea, Marilena ^b  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Gonadotropin releasing hormone; Hormone dependent tumors; In vitro fertilization; LH RH antagonists; Luteinizing hormone releasing hormone; Non peptidic LH RH antagonists; Tumor therapy

Indexed keywords

ABARELIX; ACYLINE; AMYLOID BETA PROTEIN[25-35]; ANDROSTANOLONE; AZALINE B; BUSERELIN; CETRORELIX; DEGARELIX; ELAGOLIX; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; GONADOTROPIN; ITURELIX; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; ORNIRELIX; OZARELIX; PLENAXIX; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TEVERELIX; UNCLASSIFIED DRUG;

ANAPHYLAXIS; BRONCHITIS; CANCER INHIBITION; CANCER THERAPY; CHEMICAL STRUCTURE; CLINICAL TRIAL; DOWN REGULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG STABILITY; ENDOMETRIOSIS; FERTILIZATION IN VITRO; GONADOTROPIN RELEASE; HEADACHE; HISTAMINE RELEASE; HOT FLUSH; HUMAN; LIBIDO DISORDER; LOW DRUG DOSE; LUTEINIZING HORMONE RELEASE; NONHUMAN; OVARY CANCER; OVULATION INDUCTION; PATENT; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENDOMETRIOSIS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASMS; PATENTS AS TOPIC; PROSTATIC HYPERPLASIA;

EID: 71449126523     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903410237     Document Type: Review

References (100)

1. Matsuo H, Baba Y, Nair RM, et al. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:1334-1339
2. Kastin AJ, Coy DH, Schally AV, Zadina JE. Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior. Pharmacol Biochem Behav 1980;13:913-914
3. Carmel PW, Araki S, Ferin M. Pituitary stalk portal blood collection in rhesus monkeys: Evidence for pulsatile release of gonadotropin-releasing hormone (GnRH). Endocrinology 1976;99:243-248
4. Redding TW, Kastin AJ, Gonzales-Barcena D, et al. The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing LH (hormone-RH) in man. J Clin Endocrinol Metab 1973;37:626-631
5. Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science 1978;202:631-633
6. Schultze-Mosgau A, Griesinger G, Altgassen C, et al. New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs 2005;14:1085-1097
7. Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci 2005;88:5-28
8. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-2320
9. Padula AM. GnRH analogues - agonists and antagonists. Anim Reprod Sci 2005;88:115-126
10. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol 2004;115S:44-56
11. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007;22:2805-2813
12. Reissmann T, Schally AV, Bouchard P, et al. The LHRH antagonist cetrorelix: A review. Hum Reprod Update 2000;6:322-331
13. Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. Rev Urol 2001;3:S23-8
14. Schmidt F, Sundaram K, Thau RB, Bardin CW. [Ac-D-NAL(2)1,4FD-Phe2, D-Trp3,D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 1984;29:283-289
15. Bajusz S, Csernus VJ, Janáky T, et al. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 1988;32:425-435
16. Cook T, Sheridan WF. Development of GnRH antagonists for prostate cancer: New approaches to treatment. Oncologist 2000;5:162-168
17. Nestor JJ Jr, Tahilramani R, Ho TL, et al. Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J Med Chem 1992;35:3942-3948
18. Jiang G, Stalewski J, Galyean R, et al. GnRH antagonists: A new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001;44:453-467
19. Deghenghi R, Boutignon F, Wüthrich P, Lenaerts V. Antarelix (EP 24332) a novel water soluble LHRH antagonist. Biomed Pharmacother 1993;47:107-110
20. Beckers T, Bernd M, Kutscher B, et al. Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. Biochem Biophys Res Commun 2001;289:653-663
21. Janecka A, Janecki T, Shan S, et al. Novel, potent luteinizing hormone-releasing hormone antagonists withis in water. J Med Chem 1994;37:2238-2241
22. Phillips A, Hahn DW, McGuire JL, et al. Evaluation of the anaphylactoid activity of a new LHRH antagonist. Life Sci 1988;43:883-888
23. Rivier JE, Jiang G, Porter J, et al. Gonadotropin-releasing hormone antagonists: Novel members of the azaline B family. J Med Chem 1995;38:2649-2662
24. Rivier J, Porter J, Hoeger C, et al. Gonadotropin-releasing hormone antagonists with Nomega- triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6. J Med Chem 1992;35:4270-4278
25. Herbst KL. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 2003;3:660-666
26. Huhtainemi I, White R, McArdle CA, Persson B-E. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metabol 2008;20:43-50
27. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-177
28. Kovács M, Szepesházi K, Schally AV. Endocrine and antineoplastic effects of antagonistic and cytotoxic analogs of luteinising hormone-releasing hormone. In: Kovács M, Merchenhalter I, editors, Neuropeptides and peptide analogs. Research Signpost, Kerela, India; 2009. p. 33-57
29. Weckermann D, Harzman R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-284
30. Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix. J Pharmacol Exp Ther 2002;301:95-102
31. Ferring BV. GnRH antagonists. US5925730; 1999
32. Bernd M, Kutscher B, Gunther E, et al. Methods of treatment using novel LHRH antagonists having improved solubility properties. US20060281685; 2006
33. Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof. EP1939204; 2008, WO2007046392; 2007
34. Ardana Bioscience Ltd. Sustained release of microcrystalline peptide suspension. US20060229238; 2006
35. Praecis Pharmaceutical, Inc. Pharmaceutical formulations for sustained drug delivery. WO2007022254; 2007
36. AEterna Zentaris GmbH. Application of initial doses LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits. WO2008017664; 2008, US20080032935; 2008, EP1891964; 2008
37. Balance Pharmaceutical, Inc. Nasal-spray formulation and method. US6958142; 2005
38. AEterna Zentaris GmbH. Injectable solution of an LHRH antagonist. US7214662; 2007
39. Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996;11:917-919
40. Janssens RM, Lamback CB, Vermeiden JP, et al. Dose-finding study of triptorelin acetate for prevention of premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15:2333-2340
41. Tarlatzis BC, Fauser BC, Kolibianakis EM, et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333-340
42. Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005;365:1807-1816
43. Verberg MF, Macklon NS, Nargund G, et al. Mild ovarian stimulation for IVF. Hum Reprod Update 2009;15:13-29
44. AEterna Zentaris GmbH. LHRH-antagonists in the treatment of fertility disorders. US7393834; 2008
45. Mezó G, Manea M, Szabó I, et al. New derivatives of GnRH as potential anticancer therapeutic agents. Curr Med Chem 2008;15:2366-2379
46. Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. Rev Urol 2001;3S:1-9
47. Emons G, Gründker C, Günthert AR, et al. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003;10:291-299
48. Keller G, Schally AV, Gaiser T, et al. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with cytotoxic LHRH analogue AN-207. Eur J Cancer 2005;41:2196-2202 (Pubitemid 41337963)
49. Gründker C, Günthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002;146:1-14
50. Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007;13:143-162
51. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405
52. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205
53. Gründker C, Völker P, Günthert AR, Emons G. Antiproliferative signaling of LHRH in human endometrial and ovarian cancer cells through G-protein ai-mediated activation of phosphotyrosine phosphatase. Endocrinology 2001;142:2369-2380
54. Maudsley S, Davidson L, Pawson AJ, et al. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533-7544
55. Gründker C, Schlotawa L, Viereck V, et al. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 2004;151:141-149
56. Fister S, Günthert AR, Emons G, Gründker C. Gonadotropin-releasing hormone type II antagonists induce apoptotic death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007;67:1750-1756
57. Nagy A, Schally AV, Armatis P, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-7273
58. Tulane Educational Fund. Targeted cytotoxic anthracycline analogs. US6184374; 2001
59. AEterna Zentaris GmbH. Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof. US20080090758; 2008
60. Szabó I, Manea M, Orbán E, et al. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem 2009;20:656-665
61. Tulane Educational Fund. LHRH antagonists. US5198533; 1993
62. Reissmann T, Engel J, Kutscher B, et al. The LHRH antagonist Cetrorelix. Drugs Future 1994;19:228-237
63. AEterna Zentaris GmbH. Preparation and use of oligopeptide lyophilisate for gonad protection. US6867191; 2005
64. AEterna Zentaris GmbH. Method for producing steril suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments. WO2006069641; 2006
65. Asta Medica Aktiengesellschaft. Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation. US6022860; 1998
66. Matikainen T, Ding YQ, Vergara M, et al. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol 1992;7:820-825
67. Olivennes F, Cuncha-Filho JS, Fanchin R, et al. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279-290
68. Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 1997;12:2028-2035
69. Comaru-Schally AM, Brannan W, Schally AV, et al. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998;83:3826-3831
70. Telegdy G, Tanaka M, Schally AV. Effects of the LHRH antagonist Cetrorelix on the brain function in mice. Neuropeptides 2009;43:229-234
71. AEterna Zentaris GmbH. Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists. US7288517; 2007
72. Ben-Josef E, Yang SY, Ji TH, et al. Hormone-refractory prostate cancer cells expresses functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161:970-976
73. Praecis Pharmaceuticals, Inc. Methods for treating FSH related conditions with GnRH antagonists. US7109171; 2007
74. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormon antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-1589
75. Wong SL, Lau DT-W, Baughman SA, et al. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin releasing hormone (GnRH) antagonists after subcutaneous, continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 2003;73:304-311
76. Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery. US5968895; 1999
77. Wong SL, Lau DT-W, Baughman SA, et al. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin releasing hormone (GnRH) antagonists, in healthy men ages 50 to 75. J Clin Pharmacol 2004;44:495-502
78. Van Poppel H, Nilsson S. Testosteron surge: Rationale for gonadotropin-releasing hormon blockers? Urology 2008;71:1001-1006
79. Steiner MS, Veverka KA. Composition comprising a SARM and GnRH agonist or an GnRH antagonist, and methods of use thereof. US20060287282; 2006
80. Felberbaum R, Diedrich K. Ovarian stimulation for in-vitro fertilization/ intracytoplasmic sperm injection with gonadotrophins and gonadotrophin- releasing hormone analogues: Agonists and antagonists. Hum Reprod 1999;14:207-221
81. Meldrum DR, Scott RT, Levy MJ, et al. Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins and early pregnancy loss. Fertil Steril 2009;91:1963-1965
82. Bellver J, Albert C, Lambarta E, Pellicer A. Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pretreatment. Fertil Steril 2007;87:1098-1101
83. Meldrum DR, Cassidenti DL, Rosen GF, et al. Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles. J Assist Reprod Genet 2008;25:417-420
84. Rivier J. GnRH analogues towards the next millenium. In: Lunenfeld B, editor, GnRH Analogues - TheState of Art at the Millenium; Parthenon Publishing: Carnforth, UK; 1999. p. 31-45
85. Haviv F, Fitzpatrick TD, Nichols CJ, et al. The effect of of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonists. J Med Chem 1993;36:928-933 (Pubitemid 23118789)
86. Ferring BV. GnRH antagonists being modified in positions 5 and 6. WO1998046634; 1998, US6214798; 2001
87. Doehn C, Sommerauer M, Jocham D. Drug evaluation: Degarelix - a potential new therapy for prostate cancer. IDrugs 2006;9:565-572
88. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008;102:1531-1538
89. Persson B-E, Olesen TK, Jensen J-K. Degarelix: A new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90:235-244
90. Doehn C, Sommerauer M, Jocham D. Degarelix and its therapeutic potential in the treatment of prostate cancer. Clin Intervent Aging 2009;4:215-223
91. Samant MP, Gulyas J, Hong DJ, et al. Iterative approach to the discovery of novel degarelix analogues: Substitutions at positions 3, 7, and 8. Part II. J Med Chem 2005;48:4851-4860
92. Samant MP, Gulyas J, Hong DJ, et al. Synthesis, in vivo and in vitro biological activity of novel azaline B analogs. Bioorg Med Chem Lett 2005;15:2894-2897
93. AEterna Zentaris GmbH. LHRH antagonists having improved solubility properties. US7148195; 2006
94. AEterna Zentaris GmbH. Use of LHRH antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity. EP1967202; 2008
95. Pelletier JC, ChengalvalaM,Cottom J, et al. 2-Phenyl-4- piprazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing (GnRH) receptor. Bioorg Med Chem 2008;16:6617-6640
96. Heitman LH, Ijzerman AP. G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: A case for GnRH, LH, FSH, and GPR54 receptor ligands. Med Res Rev 2008;28:975-1011
97. Betz SF, Zhu YF, Chen C, Struthers RS. Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem 2008;51:3331-3348
98. Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto. WO2005007633; 2005, US7229995; 2007
99. Chen C, Wu D, Guo Z, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro- 3- methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6- dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino} butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 2008;51:7478-7485
100. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94:545-551